Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Do we know the true mechanism of action of the DPP‐4 inhibitors?
Emilie S. Andersen, Carolyn F. Deacon, Jens J. Holst
Diabetes Obesity and Metabolism (2017) Vol. 20, Iss. 1, pp. 34-41
Closed Access | Times Cited: 95

Showing 26-50 of 95 citing articles:

Therapeutic Potential of Peptides Derived from Animal Venoms: Current Views and Emerging Drugs for Diabetes
Aimee Coulter‐Parkhill, Stephen McClean, Victor A. Gault, et al.
Clinical Medicine Insights Endocrinology and Diabetes (2021) Vol. 14
Open Access | Times Cited: 36
Dipeptidyl Peptidase-4 Inhibitors and Diabetic Kidney Disease: A Narrative Review
Rodrigo Daza-Arnedo, Jorge-Eduardo Rico-Fontalvo, Nehomar Pájaro-Galvis, et al.
Kidney Medicine (2021) Vol. 3, Iss. 6, pp. 1065-1073
Open Access | Times Cited: 36
Generation of dipeptidyl peptidase IV (DPP-IV) inhibitory peptides during the enzymatic hydrolysis of tropical banded cricket (Gryllodes sigillatus) proteins
Alice B. Nongonierma, Candice Lamoureux, Richard J. Fitzgerald
Food & Function (2017) Vol. 9, Iss. 1, pp. 407-416
Open Access | Times Cited: 41
The Biological Impacts of Sitagliptin on the Pancreas of a Rat Model of Type 2 Diabetes Mellitus: Drug Interactions with Metformin
Lamiaa M. Shawky, Ahmed A. Morsi, Eman El Bana, et al.
Biology (2019) Vol. 9, Iss. 1, pp. 6-6
Open Access | Times Cited: 40
Repositioning of dipeptidyl peptidase-4 inhibitors and glucagon like peptide-1 agonists as potential neuroprotective agents
Shaker A. Mousa, BassamM Ayoub
Neural Regeneration Research (2019) Vol. 14, Iss. 5, pp. 745-745
Open Access | Times Cited: 39
A Novel Dipeptidyl Peptidase IV Inhibitory Tea Peptide Improves Pancreatic β-Cell Function and Reduces α-Cell Proliferation in Streptozotocin-Induced Diabetic Mice
Yating Lu, Peng Lü, Yu Wang, et al.
International Journal of Molecular Sciences (2019) Vol. 20, Iss. 2, pp. 322-322
Open Access | Times Cited: 37
Dipeptidyl Peptidase-IV Inhibitory Activity and Related Molecular Mechanism of Bovine α-Lactalbumin-Derived Peptides
Jing Gao, Han Gong, Xueying Mao
Molecules (2020) Vol. 25, Iss. 13, pp. 3009-3009
Open Access | Times Cited: 33
Sitagliptin inhibits the survival, stemness and autophagy of glioma cells, and enhances temozolomide cytotoxicity
Fangting You, Cheng Li, Shicheng Zhang, et al.
Biomedicine & Pharmacotherapy (2023) Vol. 162, pp. 114555-114555
Open Access | Times Cited: 12
A randomized clinical trial of the efficacy and safety of sitagliptin compared with dapagliflozin in patients with type 2 diabetes mellitus and mild renal insufficiency: The CompoSIT‐R study
Russell Scott, Jerry D. Morgan, Zachary Zimmer, et al.
Diabetes Obesity and Metabolism (2018) Vol. 20, Iss. 12, pp. 2876-2884
Open Access | Times Cited: 37
Discovery of Novel DPP-IV Inhibitors as Potential Candidates for the Treatment of Type 2 Diabetes Mellitus Predicted by 3D QSAR Pharmacophore Models, Molecular Docking and De Novo Evolution
Azizullo Musoev, Sodik Numonov, Zhu‐Hong You, et al.
Molecules (2019) Vol. 24, Iss. 16, pp. 2870-2870
Open Access | Times Cited: 34
Repurposing anti-diabetic drugs for the treatment of Parkinson's disease: Rationale and clinical experience
Thomas Foltynie, Dilan Athauda
Progress in brain research (2019), pp. 493-523
Closed Access | Times Cited: 34
COVID-19 and the Heart and Vasculature
Bernard Kadosh, Michael Garshick, Juan Gaztañaga, et al.
Arteriosclerosis Thrombosis and Vascular Biology (2020) Vol. 40, Iss. 9, pp. 2045-2053
Open Access | Times Cited: 28
Transepithelial Transport of the Bifunctional Peptide IPYWTY Indirectly Induced Insulin Release Mediated by Active GLP-1
Mingkai Zhang, Ling Zhu, Hui Zhang, et al.
Journal of Agricultural and Food Chemistry (2023) Vol. 71, Iss. 34, pp. 12749-12756
Closed Access | Times Cited: 10
The impacts and mechanisms of dietary proteins on glucose homeostasis and food intake: a pivotal role of gut hormones
Mingkai Zhang, Ling Zhu, Gangcheng Wu, et al.
Critical Reviews in Food Science and Nutrition (2023), pp. 1-15
Closed Access | Times Cited: 10
Have dipeptidyl peptidase-4 inhibitors ameliorated the vascular complications of type 2 diabetes in large-scale trials? The potential confounding effect of stem-cell chemokines
Milton Packer
Cardiovascular Diabetology (2018) Vol. 17, Iss. 1
Open Access | Times Cited: 32
Liraglutide and cardiovascular outcomes in a real world type 2 diabetes cohort
Marco Mirani, Giuseppe Favacchio, Eliseo Serone, et al.
Pharmacological Research (2018) Vol. 137, pp. 270-279
Closed Access | Times Cited: 30
Characterization of Novel Dipeptidyl Peptidase-IV Inhibitory Peptides from Soft-Shelled Turtle Yolk Hydrolysate Using Orthogonal Bioassay-Guided Fractionations Coupled with In Vitro and In Silico Study
Nhung Thi Phuong Nong, Yu‐Kuo Chen, Wen‐Ling Shih, et al.
Pharmaceuticals (2020) Vol. 13, Iss. 10, pp. 308-308
Open Access | Times Cited: 26
Molecules Isolated from Mexican Hypoglycemic Plants: A Review
Sonia Escandón-Rivera, Rachel Mata, Adolfo Andrade‐Cetto
Molecules (2020) Vol. 25, Iss. 18, pp. 4145-4145
Open Access | Times Cited: 24
Functional foods with dipeptidyl peptidase‐4 inhibitory potential and management of type 2 diabetes: A review
Mutiu Idowu Kazeem, Habeeb Adebodun Bankole, Olabisi Ogunrinola, et al.
Food Frontiers (2021) Vol. 2, Iss. 2, pp. 153-162
Open Access | Times Cited: 21
Hypoglycemic effect of camel milk powder in type 2 diabetic patients: A randomized, double‐blind, placebo‐controlled trial
Yajie Zheng, Fang Wu, Ming Zhang, et al.
Food Science & Nutrition (2021) Vol. 9, Iss. 8, pp. 4461-4472
Open Access | Times Cited: 21
Sacubitril/Valsartan Augments Postprandial Plasma Concentrations of Active GLP-1 When Combined With Sitagliptin in Men
Nicolai J. Wewer Albrechtsen, Peter Mark, Dijana Terzic, et al.
The Journal of Clinical Endocrinology & Metabolism (2019) Vol. 104, Iss. 9, pp. 3868-3876
Open Access | Times Cited: 24
Characterization of DPP-IV Inhibitory Peptides Using an In Vitro Cell Culture Model of the Intestine
Ritian Jin, Jiaqi Shang, Xiangyu Teng, et al.
Journal of Agricultural and Food Chemistry (2021) Vol. 69, Iss. 9, pp. 2711-2718
Closed Access | Times Cited: 20
Cognitive protection of incretin‐based therapies in patients with type 2 diabetes mellitus: A systematic review and meta‐analysis based on clinical studies
Sanbao Chai, Fengqi Liu, Shuqing Yu, et al.
Journal of Diabetes Investigation (2023) Vol. 14, Iss. 7, pp. 864-873
Open Access | Times Cited: 8
Use of DPP4 Inhibitors and GLP-1 Receptor Agonists and Risk of Intestinal Obstruction: Scandinavian Cohort Study
Peter Ueda, Viktor Wintzell, Mads Melbye, et al.
Clinical Gastroenterology and Hepatology (2023) Vol. 22, Iss. 6, pp. 1226-1237.e14
Open Access | Times Cited: 8
Release of dipeptidyl peptidase IV inhibitory peptides from salmon (Salmosalar) skin collagen based on digestion–intestinal absorption invitro
Ritian Jin, Xiangyu Teng, Minhe Liao, et al.
International Journal of Food Science & Technology (2021) Vol. 56, Iss. 7, pp. 3507-3518
Closed Access | Times Cited: 16

Scroll to top